603676.SH
卫信康
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.14
−2.04%Aug 31, 2026, 08:42 UTC
Weixin Kang's wholly-owned subsidiary Yangpu Jingtai Pharmaceutical received approval from China's National Medical Products Administration for a supplementary application for Potassium Aspartate Injection, adding a new specification and deemed to pass consistency evaluation.
Source:Aug 27, 2026, 09:08 UTC
Weixinkang announced its 2026 first-half results: net profit attributable to shareholders was 143 million yuan, down 21.81% year-on-year.
Source: